Department of Vermont Health Access
Pharmacy Benefits Management Program

DUR Board Meeting Agenda

May 14, 2013  6:00 – 8:30 p.m.

1. Executive Session 6:00 - 6:30
   - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

2. Introductions and Approval of DUR Board Minutes 6:30 - 6:35
   (Public Comment Prior to Board Action)

3. DVHA Pharmacy Administration Updates 6:35 - 6:55
   - Updates
   - Center for Evidence Based Policy Update
   - Psychotherapeutic Monitoring Quality Improvement Collaborative (PMQIC)

4. Medical Director Update 6:55 - 6:55
   - Clinical Programs Update
   - Prescriber Comments

5. Follow-up Items from Previous Meetings 6:55 - 7:15
   - Methadone for Chronic Pain
   - Suboxone® Tablet to Film transition

6. RetroDUR/DUR 7:15 – 7:25
   - Second Reconsiderations by Medical Director
   - Xyrem® (sodium oxybate)

7. Clinical Update: Drug Reviews 7:25 – 7:45
   (Public comment prior to Board action)

   Abbreviated New Drug Reviews
   - Delzicol (mesalamine delayed release) Oral Capsule
   - Xyrem® (sodium oxybate) Oral Solution

   Full New Drug Reviews
   - Aubagio® (teriflunomide) Oral Tablet
   - Linzess® (linaclotide) Oral Capsule
8. Therapeutic Drug Classes – Periodic Review 7:45 – 8:15
(Public comment prior to Board action)
Class review documents available on DVHA web site 05/14/2013 @ 12 Noon
- Anti-diabetics: Oral
  - Alpha Glucosidase Inhibitors
  - Biguanides
  - Dipeptidyl Peptidase (DPP-4) Inhibitors
  - Meglitinides
  - Sulfonylureas
  - Thiazolidinediones
- Anti-diabetics: Injectable:
  - Incretin Mimetics & Amylinomimetics
  - Insulin
- Anti-infectives: Antibiotics:
  - Cephalosporins - 1st Generation
  - Cephalosporins - 3rd Generation
  - Macrolides and Ketolides
- Constipation: Chronic, IBS-C or Opioid Induced
- Phosphodiesterase-4 Inhibitors
- Pulmonary:
  - Beta Agonists and Anticholinergic Combinations
- Smoking Cessation Agents

9. New Managed Therapeutic Drug Classes 8:15 – 8:15
(Public comment prior to Board action)
- None

10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products 8:15 – 8:25
(Public comment prior to Board action)
- Pediatric Antipsychotic Medications

11. General Announcements 8:25– 8:30
Selected FDA Safety Alerts
- Potiga (Ezogabine): Drug Safety Communication - Linked To Retinal Abnormalities And Blue Skin Discoloration
- Samsca (Tolvaptan): Drug Safety Communication - FDA Limits Duration and Usage Due To Possible Liver Injury Leading to Organ Transplant or Death
- Valproate Anti-Seizure Products: Drug Safety Communication - Contraindicated for Pregnant Women for Prevention of Migraine Headaches

12. Adjourn 8:30